Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 5;14(1):2.
doi: 10.1186/s13195-021-00949-7.

Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer's disease

Byron Creese  1 , Zahinoor Ismail  2
Affiliations
Review

Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer's disease

Byron Creese et al. Alzheimers Res Ther. .

Abstract

Background: Late-life onset neuropsychiatric symptoms are established risk factors for dementia. The mild behavioral impairment (MBI) diagnostic framework was designed to standardize assessment to determine dementia risk better. In this Mini Review, we summarize the emerging clinical and biomarker evidence, which suggests that for some, MBI is a marker of preclinical Alzheimer's disease. MAIN: MBI is generally more common in those with greater cognitive impairment. In community and clinical samples, frequency is around 10-15%. Mounting evidence in cognitively normal samples links MBI symptoms with known AD biomarkers for amyloid, tau, and neurodegeneration, as well as AD risk genes. Clinical studies have found detectable differences in cognition associated with MBI in cognitively unimpaired people.

Conclusion: The emerging evidence from biomarker and clinical studies suggests MBI can be an early manifestation of underlying neurodegenerative disease. Future research must now further validate MBI to improve identification of those at the very earliest stages of disease.

Keywords: Biomarkers; Cognition; Mild behavioral impairment; Neuropsychiatric symptoms; Preclinical AD.

PubMed Disclaimer

Conflict of interest statement

BC declares that they have no competing interests.

ZI has received honoraria/consulting fees from Lundbeck and Otsuka outside the submitted work. His institution has received funds from Acadia, Biogen, Roche, and Sunovion.

References

    1. Masters MC, Morris JC, Roe CM. “Noncognitive” symptoms of early Alzheimer disease: a longitudinal analysis. Neurology. 2015;84:617–622. doi: 10.1212/WNL.0000000000001238. - DOI - PMC - PubMed
    1. Kohler S, Allardyce J, Verhey FR, McKeith IG, Matthews F, Brayne C, et al. Cognitive decline and dementia risk in older adults with psychotic symptoms: a prospective cohort study. Am J Geriatr Psychiatry. 2013;21:119–128. doi: 10.1016/j.jagp.2012.10.010. - DOI - PubMed
    1. Donovan NJ, Amariglio RE, Zoller AS, Rudel RK, Gomez-Isla T, Blacker D, et al. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry. 2014;22:1642–1651. doi: 10.1016/j.jagp.2014.02.007. - DOI - PMC - PubMed
    1. Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, et al. The Alzheimer’s disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Dis Extra. 2014;4:509–516. doi: 10.1159/000357775. - DOI - PMC - PubMed
    1. Geda YE, Roberts RO, Mielke MM, Knopman DS, Christianson TJH, Pankratz VS, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. Am J Psychiatry. 2014;171:572–581. doi: 10.1176/appi.ajp.2014.13060821. - DOI - PMC - PubMed

Publication types

Grants and funding